



## Screening Questionnaire for Potential Monoclonal Infusion Sites:

1.	Do you have space for a dedicated area for infusion with appropriate infection control precautions?	<input type="checkbox"/> Yes <input type="checkbox"/> No
2.	Do you have the ability to mix utilizing aseptic technique and infuse IV medications (i.e., staff competency)?	<input type="checkbox"/> Yes <input type="checkbox"/> No
3.	Do you have staff on-site, or available to come on-site, who are competent to administer IV infusions?	<input type="checkbox"/> Yes <input type="checkbox"/> No
3a.	If no, have you considered forming collaborations with other local community clinics, medical facilities, EMS, etc. to provide such staff to accommodate infusion appointments?	<input type="checkbox"/> Yes <input type="checkbox"/> No
4.	Do you meet all the requirements of the EUA COVID-19 monoclonal antibody Letter or Authorizations for the respective products (e.g., you have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS); tracking serious adverse events; appropriate storage conditions for product; reporting utilization data, etc.)? <sup>1</sup>	<input type="checkbox"/> Yes <input type="checkbox"/> No

- **You answered “Yes” to all the questions above**

Your site has the capability and you are prepared to begin administration of COVID-19 EUA monoclonal antibody treatments. Proceed to direct ordering of product.

- Information on [direct ordering](https://www.phe.gov/emergency/events/COVID19/healthcare-facilities/Pages/default.aspx#step3) is available at:  
<https://www.phe.gov/emergency/events/COVID19/healthcare-facilities/Pages/default.aspx#step3>.
- Additional [information for infusion sites](https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/Distribution.aspx) regarding COVID-19 monoclonal antibody therapeutics is available at:  
<https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/Distribution.aspx>.

- **You answered “No” to any of the questions above**

Your site does not currently have the capability to administer monoclonal antibody treatments. When conducting COVID tests, screen patient’s eligibility to receive COVID-19 EUA monoclonal antibody treatment. For patients with positive COVID tests, determine if there is an existing monoclonal infusion facility within close proximity of the Urgent Care Center. [Existing Monoclonal Infusion sites](https://protect-public.hhs.gov/pages/therapeutics-distribution#distribution-locations) can be located at: <https://protect-public.hhs.gov/pages/therapeutics-distribution#distribution-locations>. If there is a site in close proximity, contact the infusion site to determine the process for referral from the urgent care to the existing infusion site. If the existing site has the capacity for additional infusions, this may be an alternative to standing up the urgent care center as a new infusion site. An ideal workflow includes the patient having an appointment for monoclonal infusion scheduled at the time they receive their positive COVID test result.

**Please direct questions or requests for additional information to:**

**[COVID19Therapeutics@hhs.gov](mailto:COVID19Therapeutics@hhs.gov)**

<sup>1</sup> [Casirivimab/imdevimab Letter of Authorization](https://www.fda.gov/media/143891/download): <https://www.fda.gov/media/143891/download>; [Bamlanivimab Letter of Authorization](https://www.fda.gov/media/143602/download): <https://www.fda.gov/media/143602/download>; [Bamlanivimab/etesevimab Letter of Authorization](https://www.fda.gov/media/145801/download): <https://www.fda.gov/media/145801/download>